Jessica Adkins
Acute Care · Huntington, WVNPI 1366108060
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $572 and has fallen 84.0% since, to $91 in 2025.
Across 33 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$137
- Ambu Inc.$104
- Myriad Genetic Laboratories, Inc.$88
- AstraZeneca$77
- AbbVie$77
- GSK$49
- plus $249 from 11 others
What the payments were for
- Food & beverage$782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $137 |
| Ambu Inc. | 1 | $104 |
| Myriad Genetic Laboratories, Inc. | 4 | $88 |
| AstraZeneca | 4 | $77 |
| AbbVie | 4 | $77 |
| GSK | 2 | $49 |
| AVEO Pharmaceuticals, Inc. | 2 | $39 |
| Convatec Inc. | 1 | $38 |
| Seagen Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
| Bayer | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Novocure Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$782 in reported general payments places this provider in the 75th percentile of 51 acute care providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $1,057 |
| Cephalexin | 25 | $525 |
| Finasteride | 31 | $485 |
| Tamsulosin Hcl | 41 | $468 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $459 |
| Levofloxacin | 66 | $210 |
| Fluconazole | 15 | $183 |
| Ciprofloxacin Hcl | 19 | $70 |
Paid to pharmacies, not to this prescriber.
Other acute care in Huntington
- Eric PingHuntington$35K
- Jessica SparksHuntington$3K
- Heather HoltonHuntington$2K
- Jeffrey RoweHuntington$600
- Stephen MethenyHuntington$417
- Suzanne SpoonerHuntington$311
- Kyle RyderHuntington$122
- Anthony HayesHuntington$122
- Brandi WattsHuntington$37
- Ashley DenningHuntington$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.